|1.||Yalcin, Murat: 4 articles (05/2014 - 11/2005)|
|2.||Giese, Alf: 3 articles (02/2010 - 02/2002)|
|3.||Savci, Vahide: 2 articles (05/2014 - 11/2005)|
|4.||Westphal, Manfred: 2 articles (02/2010 - 02/2002)|
|5.||Topuz, Bora B: 1 article (05/2014)|
|6.||Altinbas, Burcin: 1 article (05/2014)|
|7.||Saha, Sikha: 1 article (05/2014)|
|8.||Yilmaz, Mustafa S: 1 article (05/2014)|
|9.||Batten, Trevor F: 1 article (05/2014)|
|10.||Gordon, John B: 1 article (04/2012)|
|1.||Right Ventricular Hypertrophy
02/01/2009 - "Thus, the specific thromboxane synthase inhibitor furegrelate increases death response induced by gamma-radiation in glioma cells in vitro and sensitizes experimental gliomas to radiation treatment in vivo."
02/01/2009 - "Pre-treatment of glioma cells with furegrelate increases radiation sensitivity of cultured glioma cells. "
02/01/2009 - "The impact of furegrelate on the sensitivity of human glioma cells to gamma-irradiation was analyzed using colony formation assay in vitro and an orthotopic mouse model in vivo. "
02/01/2009 - "Furegrelate, a specific inhibitor of thromboxane synthase, blocks cell motility, induces apoptosis and increases sensitivity to drug induced apoptosis in human glioma cells in vitro. "
02/01/2002 - "In this study, we demonstrate that the treatment of human glioma cells with the specific thromboxane synthase inhibitor furegrelate leads first to caspase activation (detectable 6 h after treatment), then to DNA fragmentation (24-48 h after treatment) and subsequent cell death. "
01/01/1985 - "Despite the significant inhibition of platelet aggregation and TXB2 production, thrombus mass was not reduced: control, 32.0 +/- 5.9 mg (n = 7); U-63557A, 30.8 +/- 12.0 mg (n = 5, p = NS). "
01/01/1985 - "The actions of the thromboxane synthetase inhibitor, U-63557A, were evaluated in vivo in anesthetized open-chest dogs by inducing left circumflex coronary artery (LCCA) thrombosis with low amperage electrical stimulation (100 microA for 6 h) of the intimal surface of the vessel, and ex vivo by assessing platelet aggregation and TXB2 production. "
01/01/1989 - "Furegrelate sodium is a thromboxane synthetase inhibitor with potential for the treatment of various diseases including hypertension, thrombosis, and renal disorders. "
02/01/2010 - "Furegrelate, a specific inhibitor of TXSA, significantly inhibited tumor growth in an orthotopic glioblastoma model by inducing proapoptotic, antiproliferative, and antiangiogenic effects. "
02/01/2009 - "Treatment of experimental gliomas with suboptimal doses of radiation and furegrelate results in a significant decrease in tumor volumes compared to untreated controls. "
|5.||Hypotension (Low Blood Pressure)
11/01/2005 - "The increase in brain endogenous TXA2 levels involves a decrease in blood pressure evoked by haemorrhage because the blockade of TXA2 synthesis by furegrelate pretreatment attenuated the haemorrhagic hypotension. "
08/01/2011 - "Pretreatments with the nonselective COX inhibitor indomethacin (200 μg; i.c.v.) or the TXA(2) synthesis inhibitor furegrelate (250 or 500 μg; i.c.v.) were made to test the role of central COX activity and, subsequently, the TXA(2) signaling pathway in the melittin- or AA-mediated reversal of hemorrhagic hypotension. "
|4.||Thromboxane A2 (A2, Thromboxane)
|7.||Caspase 3 (Caspase-3)
|10.||6-Ketoprostaglandin F1 alpha (6 Ketoprostaglandin F1 alpha)